CA3164202A1 - Novel chroman derivatives having estrogen receptor degradation activity and uses thereof - Google Patents
Novel chroman derivatives having estrogen receptor degradation activity and uses thereofInfo
- Publication number
- CA3164202A1 CA3164202A1 CA3164202A CA3164202A CA3164202A1 CA 3164202 A1 CA3164202 A1 CA 3164202A1 CA 3164202 A CA3164202 A CA 3164202A CA 3164202 A CA3164202 A CA 3164202A CA 3164202 A1 CA3164202 A1 CA 3164202A1
- Authority
- CA
- Canada
- Prior art keywords
- dione
- piperazin
- piperidine
- oxoisoindolin
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962947213P | 2019-12-12 | 2019-12-12 | |
| US62/947,213 | 2019-12-12 | ||
| PCT/US2020/027895 WO2021118629A1 (en) | 2019-12-12 | 2020-04-13 | Novel chroman derivatives having estrogen receptor degradation activity and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3164202A1 true CA3164202A1 (en) | 2021-06-17 |
Family
ID=70289288
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3164202A Pending CA3164202A1 (en) | 2019-12-12 | 2020-04-13 | Novel chroman derivatives having estrogen receptor degradation activity and uses thereof |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10800770B1 (https=) |
| EP (2) | EP3835298B1 (https=) |
| JP (2) | JP7662639B2 (https=) |
| KR (1) | KR102942706B1 (https=) |
| CN (2) | CN115003295B (https=) |
| CA (1) | CA3164202A1 (https=) |
| DK (1) | DK3835298T3 (https=) |
| ES (1) | ES2986594T3 (https=) |
| FI (1) | FI3835298T3 (https=) |
| MX (1) | MX2022007155A (https=) |
| WO (1) | WO2021118629A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102674902B1 (ko) | 2016-12-01 | 2024-06-14 | 아비나스 오퍼레이션스, 인코포레이티드 | 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 및 테트라히드로이소퀴놀린 유도체 |
| EP3932922A4 (en) | 2019-02-25 | 2022-05-11 | ShanghaiTech University | SULPHUR-CONTAINING COMPOUND BASED ON A GLUTARIMIDE FRAMEWORK AND ITS USE |
| WO2021023233A1 (zh) | 2019-08-05 | 2021-02-11 | 上海科技大学 | Egfr蛋白降解剂及其抗肿瘤应用 |
| IL320609A (en) | 2019-08-26 | 2025-07-01 | Arvinas Operations Inc | Methods for treating breast cancer with a history of tetrahydronaphthalene as estrogen receptor-disrupting agents |
| FI3835298T3 (fi) * | 2019-12-12 | 2024-07-29 | Accutar Biotechnology Inc | Uusia kromaanijohdannaisia, joilla on estrogeenireseptoria hajottava vaikutus, ja niiden käyttötapoja |
| WO2021133886A1 (en) * | 2019-12-23 | 2021-07-01 | Accutar Biotechnology | Combinations of estrogen receptor degraders and cyclin-dependent kinase inhibitors for treating cancer |
| CA3169011A1 (en) * | 2020-02-25 | 2021-09-02 | Xiaobao Yang | Glutarimide skeleton-based compounds and uses thereof |
| AR123492A1 (es) | 2020-09-14 | 2022-12-07 | Arvinas Operations Inc | Formas cristalinas y amorfas de un compuesto para la degradación dirigida del receptor de estrógeno |
| EP4289841A4 (en) * | 2021-02-04 | 2025-02-19 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Benzo seven-membered ring bifunctional compound and application thereof |
| WO2022187588A1 (en) * | 2021-03-04 | 2022-09-09 | The Regents Of The University Of Michigan | Small molecule degraders of estrogen receptor with cereblon ligands |
| MX2023011166A (es) * | 2021-03-29 | 2023-09-29 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Compuesto de tetrahidronaftaleno, metodo de preparacion y uso del mismo en medicina. |
| EP4377296A1 (en) | 2021-07-26 | 2024-06-05 | Arvinas Operations, Inc. | Methods of manufacturing a bifunctional compound |
| AU2022370021B2 (en) * | 2021-10-22 | 2026-04-16 | Gluetacs Therapeutics (Shanghai) Co., Ltd. | Crbn e3 ligase ligand compound, protein degrading agent developed on the basis of ligand compound, and their applications |
| CN113816927B (zh) * | 2021-11-23 | 2022-02-25 | 苏州国匡医药科技有限公司 | 一种arv-471中间体的制备方法 |
| CN117229286A (zh) | 2022-06-14 | 2023-12-15 | 海创药业股份有限公司 | 一种芳香类化合物及其制备方法及在制备雌激素受体降解剂中的用途 |
| WO2024015409A1 (en) * | 2022-07-12 | 2024-01-18 | Regents Of The University Of Michigan | Chroman derivatives as estrogen receptor degraders |
| CN116751186B (zh) * | 2022-12-23 | 2024-10-18 | 南京知和医药科技有限公司 | 一种雌激素受体调节剂的制备及其用途 |
| WO2024153025A1 (zh) * | 2023-01-16 | 2024-07-25 | 南京明德新药研发有限公司 | 取代的苯并七元环化合物及其应用 |
| CN119258223A (zh) * | 2023-07-06 | 2025-01-07 | 海创药业股份有限公司 | 一种降解雌激素受体的联合用药物及其用途 |
| WO2025245408A1 (en) | 2024-05-22 | 2025-11-27 | Accutar Biotechnology Inc. | Chroman-based compounds for treating cancer |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20010021710A1 (en) * | 1996-10-28 | 2001-09-13 | Poul Jacobsen | Novel cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes |
| IL129627A0 (en) | 1996-10-28 | 2000-02-29 | Novo Nordisk As | Novel CIS-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes |
| IL129618A0 (en) | 1996-10-28 | 2000-02-29 | Novo Nordisk As | Novel CIS-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes |
| EP1192945A3 (en) | 2000-09-21 | 2004-03-03 | Pfizer Products Inc. | Use of an estrogen agonist/antagonist for treating osteoarthritis |
| EP1465619A1 (en) | 2002-01-14 | 2004-10-13 | Nordic Bioscience A/S | Suppression of cartilage degradation via the estrogen receptor |
| WO2003063659A1 (de) | 2002-02-01 | 2003-08-07 | Danny Bellens | Ablageständer |
| CA2512000C (en) | 2002-12-26 | 2011-08-09 | Eisai Co., Ltd. | Selective estrogen receptor modulator |
| EP2536706B1 (en) | 2010-02-11 | 2017-06-14 | Celgene Corporation | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
| EP3303326B1 (en) * | 2015-05-26 | 2020-12-16 | H. Hoffnabb-La Roche Ag | Heterocyclic estrogen receptor modulators and uses thereof |
| HK1257296A1 (zh) * | 2016-07-12 | 2019-10-18 | Accutar Biotechnology Inc. | 新的化合物及其用途 |
| KR102674902B1 (ko) * | 2016-12-01 | 2024-06-14 | 아비나스 오퍼레이션스, 인코포레이티드 | 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 및 테트라히드로이소퀴놀린 유도체 |
| FI3835298T3 (fi) * | 2019-12-12 | 2024-07-29 | Accutar Biotechnology Inc | Uusia kromaanijohdannaisia, joilla on estrogeenireseptoria hajottava vaikutus, ja niiden käyttötapoja |
-
2020
- 2020-04-13 FI FIEP20169240.7T patent/FI3835298T3/fi active
- 2020-04-13 WO PCT/US2020/027895 patent/WO2021118629A1/en not_active Ceased
- 2020-04-13 US US16/846,492 patent/US10800770B1/en active Active
- 2020-04-13 MX MX2022007155A patent/MX2022007155A/es unknown
- 2020-04-13 EP EP20169240.7A patent/EP3835298B1/en active Active
- 2020-04-13 CN CN202080092528.XA patent/CN115003295B/zh active Active
- 2020-04-13 ES ES20169240T patent/ES2986594T3/es active Active
- 2020-04-13 DK DK20169240.7T patent/DK3835298T3/da active
- 2020-04-13 KR KR1020227023616A patent/KR102942706B1/ko active Active
- 2020-04-13 JP JP2022535123A patent/JP7662639B2/ja active Active
- 2020-04-13 CN CN202510495956.1A patent/CN120665056A/zh active Pending
- 2020-04-13 EP EP24170522.7A patent/EP4420728A3/en active Pending
- 2020-04-13 CA CA3164202A patent/CA3164202A1/en active Pending
- 2020-06-22 US US16/907,548 patent/US11261178B2/en active Active
-
2025
- 2025-02-03 JP JP2025015907A patent/JP2025081364A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20210221802A1 (en) | 2021-07-22 |
| FI3835298T3 (fi) | 2024-07-29 |
| JP2023506155A (ja) | 2023-02-15 |
| MX2022007155A (es) | 2022-10-07 |
| US11261178B2 (en) | 2022-03-01 |
| WO2021118629A1 (en) | 2021-06-17 |
| DK3835298T3 (da) | 2024-07-29 |
| EP4420728A2 (en) | 2024-08-28 |
| EP3835298A1 (en) | 2021-06-16 |
| CN115003295B (zh) | 2025-05-06 |
| KR20220118460A (ko) | 2022-08-25 |
| ES2986594T3 (es) | 2024-11-12 |
| KR102942706B1 (ko) | 2026-03-20 |
| EP4420728A3 (en) | 2024-10-30 |
| CN120665056A (zh) | 2025-09-19 |
| US10800770B1 (en) | 2020-10-13 |
| JP2025081364A (ja) | 2025-05-27 |
| JP7662639B2 (ja) | 2025-04-15 |
| EP3835298B1 (en) | 2024-06-26 |
| CN115003295A (zh) | 2022-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3164202A1 (en) | Novel chroman derivatives having estrogen receptor degradation activity and uses thereof | |
| EP3675839B1 (en) | Novel compounds having estrogen receptor alpha degradation activity and uses thereof | |
| JP7307796B2 (ja) | アンドロゲン受容体分解活性を有する新規の置換キノリン－８－カルボニトリル誘導体およびその使用 | |
| US11535606B2 (en) | Substituted quinoline-8-carbonitrile derivatives with androgen receptor degradation activity and uses thereof | |
| US11220490B2 (en) | Ureas having androgen receptor degradation activity and uses thereof | |
| HK40115205A (en) | Novel chroman derivatives having estrogen receptor degradation activity and uses thereof | |
| HK40080061A (en) | Novel chroman derivatives having estrogen receptor degradation activity and uses thereof | |
| HK40041475B (en) | Substituted quinoline-8-carbonitrile derivatives having androgen receptor degradation activity and uses thereof | |
| HK40041475A (en) | Substituted quinoline-8-carbonitrile derivatives having androgen receptor degradation activity and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20240322 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250313 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250513 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250513 |